CRISPR Therapeutics is developing CTX112 for both ... cells are edited at the erythroid specific enhancer region of the BCL11A gene. This edit results in the production of high levels of fetal ...

CRISPR Therapeutics is developing CTX112 for both hematologic malignancies ... s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene.

CRISPR Therapeutics is developing CTX112 for both hematologic malignancies ... and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene. This edit results in the ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Casgevy enables CRISPR/Cas-9 to edit the BCL11A gene in stem cells to produce fetal hemoglobin ... Our most recently signed ...

Casgevy enables CRISPR/Cas-9 to edit the BCL11A gene in stem cells to produce ... Our most recently signed SPL, Kamau Therapeutics, brings our total number of SPLs to 29. We are very excited ...

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has ... by introducing a gene known as BCL11A which down-regulates the production of the adult form of the oxygen-carrying ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...